Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | GLS | O94925 | 2/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511906 | 0.80 | FFAR4 (0.44) | FFAR4GLS | |
| SCHEMBL8513265 | 0.76 | HRH3 (0.33) | — | |
| SCHEMBL5267119 | 0.74 | HRH3 (0.39) | SCD5EPHX2RBP4 | |
| SCHEMBL8511650 | 0.73 | IKBKB (0.40) | IKBKBCHUK | |
| SCHEMBL29240900 | 0.73 | FFAR4 (0.38) | FFAR4SCD | |
| SCHEMBL2589683 | 0.72 | ACACB (0.55) | — | |
| SCHEMBL2592476 | 0.71 | HRH3 (0.42) | IKBKBSCD5CHUKHMOX1SCD | |
| SCHEMBL24663590 | 0.71 | USP30 (0.38) | — | |
| SCHEMBL5267504 | 0.70 | HRH3 (0.43) | SCD5GLS | |
| SCHEMBL5266004 | 0.70 | SCD5 (0.35) | SCD5HMOX1SCDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | FFAR4 60/4885IKBKB 2286/4885SCD5 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.